Additionally, research has shown that increased TPX2 expression enhanced human CD8+ T-cell-mediated antitumor activity and amplifies therapeutic responsiveness to PD-1 inhibition in hepatocellular carcinoma patient-derived xenograft mouse models, irrespective of anti–PD-1 administration [39]. The gene discussed is CD8A; the disease is hepatocellular carcinoma.